Short-Term Treatment With Anti-CD3 Antibody Reduces the Development and Progression of Atherosclerosis in Mice

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Circulation

• Publication date

  2006-10-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.106.627430PMID 17043169
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Natural regulatory T cells control the development of atherosclerosis in mice

  2006cited by this paper
• Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

  2005cited by this paper
• Mechanisms of suppression by suppressor T cells

  2005cited by this paper
• Inflammation, atherosclerosis, and coronary artery disease.

  2005cited by this paper
• Cutting Edge: Contact-Mediated Suppression by CD4+CD25+ Regulatory Cells Involves a Granzyme B-Dependent, Perforin-Independent Mechanism1

  2005cited by this paper
• Mechanisms of suppression by suppressor T cells

  2005cited by this paper
• Differential Influence of Chemokine Receptors CCR2 and CXCR3 in Development of Atherosclerosis In Vivo

  2005cited by this paper
• Treatment with Nonmitogenic Anti-CD3 Monoclonal Antibody Induces CD4+ T Cell Unresponsiveness and Functional Reversal of Established Experimental Autoimmune Encephalomyelitis1

  2005cited by this paper
• In Vivo Instruction of Suppressor Commitment in Naive T Cells

  2004cited by this paper
• Statins as immunomodulatory agents.

  2004cited by this paper
• Differential Expression Patterns of Proinflammatory and Antiinflammatory Mediators During Atherogenesis in Mice

  2004cited by this paper
• Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation.

  2004cited by this paper
• Supporting Online Material

  2003cited by this paper
• Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

  2003cited by this paper
• Disruption of TGF-beta signaling in T cells accelerates atherosclerosis.

  2003cited by this paper
• TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes

  2003cited by this paper
• An essential role for Scurfin in CD4+CD25+ T regulatory cells

  2003cited by this paper
• CD28/B7 Regulation of Anti-CD3-Mediated Immunosuppression In Vivo1

  2003cited by this paper
• Diversity of regulatory CD4+T cells controlling distinct organ-specific autoimmune diseases

  2003cited by this paper
• Disruption of TGF-β signaling in T cells accelerates atherosclerosis

  2003cited by this paper
• Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial.

  2002cited by this paper
• Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

  2002cited by this paper
• Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

  2002cited by this paper
• Inhibition of Transforming Growth Factor-&bgr; Signaling Accelerates Atherosclerosis and Induces an Unstable Plaque Phenotype in Mice

  2001cited by this paper
• Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines.

  1999cited by this paper
• Protective role of interleukin-10 in atherosclerosis.

  1999cited by this paper
• Interleukin-10 blocks atherosclerotic events in vitro and in vivo.

  1999cited by this paper
• Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: association with TH2 cytokines not anergy.

  1999cited by this paper
• Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets.

  1998cited by this paper
• Mature mainstream TCR alpha beta+CD4+ thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse.

  1998cited by this paper
• CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice.

  1997cited by this paper
• Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis.

  1996cited by this paper
• In vivo administration of anti-murine CD3 monoclonal antibody induces selective, long-term anergy in CD8+ T cells.

  1996cited by this paper
• The autoimmune response induced by immunising female mice with recombinant human thyrotropin receptor varies with the genetic background.

  1995cited by this paper
• Natural killer and lymphokine-activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells.

  1995cited by this paper
• Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

  1995cited by this paper
• Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells.

  1994cited by this paper
• Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.

  1994cited by this paper
• Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery.

  1993cited by this paper
• Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation

  1992cited by this paper
• Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb.

  1990cited by this paper
• Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses.

  1988cited by this paper
• Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.

  1987cited by this paper
• Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent.

  1986cited by this paper
• A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants.

  1985cited by this paper
• Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts.

  1981cited by this paper

• C-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice

  2025cites this paper
• Novel UV‐B Phototherapy With a Light‐Emitting Diode Device Prevents Atherosclerosis by Augmenting Regulatory T‐Cell Responses in Mice

  2024cites this paper
• Targeting immune cell recruitment in atherosclerosis

  2024cites this paper
• The Role of Monoclonal Antibodies in the Treatment of Atherosclerosis.

  2023cites this paper
• Lymphocyte-Related Immunomodulatory Therapy with Siponimod (BAF-312) Improves Outcomes in Mice with Acute Intracerebral Hemorrhage

  2023cites this paper
• Interleukin-27 Ameliorates Atherosclerosis in ApoE−/− Mice through Regulatory T Cell Augmentation and Dendritic Cell Tolerance

  2022cites this paper
• Comparison of CD3e Antibody and CD3e-sZAP Immunotoxin Treatment in Mice Identifies sZAP as the Main Driver of Vascular Leakage

  2022cites this paper
• Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin

  2022cites this paper
• Regulatory T Cell-Enhancing Therapies to Treat Atherosclerosis

  2021cites this paper
• Experimental Agents for the Treatment of Atherosclerosis: New Directions

  2021cites this paper
• Recent Advances on the Role and Therapeutic Potential of Regulatory T Cells in Atherosclerosis

  2021cites this paper
• Anti-inflammatory and Immunomodulatory Therapies in Atherosclerosis.

  2021cites this paper
• Benzo(α)pyrene induces oxidative stress and inflammation in human vascular endothelial cells through AhR and NF-κB pathways.

  2021cites this paper
• T-Cell Molecular Modulation Responses in Atherosclerosis Anergy.

  2020cites this paper
• Effect of clopidogrel vs. aspirin on pro-atherosclerotic NLRP1 inflammasome expression in endothelial cells. ECLOAS study.

  2020cites this paper
• Effect of clopidogrel vs. aspirin on pro-atherosclerotic NLRP1 inflammasome expression in endothelial cells. ECLOAS study

  2020cites this paper
• Imaging and Targeting Coronary Artery Inflammation

  2020cites this paper
• Immunobiology of Atherosclerosis: A Complex Net of Interactions

  2019cites this paper
• Macrophages in Atherosclerosis Regression

  2019cites this paper
• Smoking affects gene expression in blood of patients with ischemic stroke

  2019cites this paper
• GSNOR modulates hyperhomocysteinemia-induced T cell activation and atherosclerosis by switching Akt S-nitrosylation to phosphorylation

  2018cites this paper
• Anti-Inflammatory Treatment

  2018cites this paper
• The Sunlight: A New Immunomodulatory Approach of Atherosclerosis.

  2017cites this paper
• Regulatory T Cell Immunity in Atherosclerosis.

  2017cites this paper
• Differential depletion of total T cells and regulatory T cells and prolonged allotransplant survival in CD3Ɛ humanized mice treated with polyclonal anti human thymocyte globulin

  2017cites this paper
• Recent advances on CD4+ T cells in atherosclerosis and its implications for therapy

  2017cites this paper
• Adaptive Response of T and B Cells in Atherosclerosis.

  2016cites this paper
• Diagnosis and Treatment of Atherosclerosis: A Review Article

  2016cites this paper
• Inflammatory cytokines in atherosclerosis: current therapeutic approaches.

  2016cites this paper
• Effect of Simvastatin Treatment on "In Vitro" NLRP1 Inflammasome Expression in Peripheral Arterial Disease.

  2016cites this paper
• Novel therapeutic concepts Inflammatory cytokines in atherosclerosis : current therapeutic approaches

  2016cites this paper
• Novel anti-inflammatory therapies for the treatment of atherosclerosis.

  2015cites this paper
• Modulation of autoimmunity and atherosclerosis - common targets and promising translational approaches against disease.

  2015cites this paper
• Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potential

  2015cites this paper
• Regulatory T cells and tolerogenic dendritic cells as critical immune modulators in atherogenesis.

  2015cites this paper
• Atheroprotective immunity and cardiovascular disease: therapeutic opportunities and challenges

  2015cites this paper
• Attenuation of early atherosclerotic lesions by immunotolerance with β2 glycoprotein I and the immunomodulatory effectors interleukin 2 and 10 in a murine model.

  2015cites this paper
• Anti-inflammatory and immune-modulatory therapies for preventing atherosclerotic cardiovascular disease.

  2015cites this paper
• Regression of atherosclerosis with anti-CD3 antibody via augmenting a regulatory T-cell response in mice.

  2014cites this paper
• Regulatory T Cells Protect Fine Particulate Matter-Induced Inflammatory Responses in Human Umbilical Vein Endothelial Cells

  2014cites this paper
• The formation of atherosclerotic plaque, its destabilisation and diagnostics

  2014cites this paper
• Fine tuning effector and regulatory T-cell dynamics: a novel tool for plaque regression?

  2014cites this paper
• CD3 Antibody and IL‐2 Complex Combination Therapy Inhibits Atherosclerosis by Augmenting a Regulatory Immune Response

  2014cites this paper
• Impairment of Circulating CD4+CD25+GARP+ Regulatory T Cells in Patients with Acute Coronary Syndrome

  2014cites this paper
• Adaptive (T and B Cells) Immunity and Control by Dendritic Cells in Atherosclerosis

  2014cites this paper
• Athero-protective immunity and cardiovascular disease: therapeutic opportunities and challenges

  2014cites this paper
• Tworzenie blaszki miazdzycowej, jej destabilizacja i diagnostyka

  2014cites this paper
• Emerging biomarkers and intervention targets for immune-modulation of atherosclerosis - a review of the experimental evidence.

  2013cites this paper
• Endocrine Regulation of T-cell Development and Peripheral T-cell Maturation

  2013cites this paper
• Immunological aspects of atherosclerosis

  2013cites this paper
• T cell-based therapies for atherosclerosis.

  2013cites this paper
• Regulatory T cells in atherosclerosis and strategies to induce the endogenous atheroprotective immune response.

  2013cites this paper
• Physiopathologie de l’athérosclérose

  2013cites this paper
• Immune Regulation in T1D and T2D: Prospective Role of Foxp3+ Treg Cells in Disease Pathogenesis and Treatment

  2013cites this paper
• Treg Inducing Adjuvants for Therapeutic Vaccination Against Chronic Inflammatory Diseases

  2013cites this paper
• Molecular biology of atherosclerosis.

  2013cites this paper
• CD4+ T cells in atherosclerosis: Regulation by platelets

  2013cites this paper
• Anti-CD3ε mAb improves thymic architecture and prevents autoimmune manifestations in a mouse model of Omenn syndrome: therapeutic implications.

  2012cites this paper
• Morbidly Obese Human Subjects Have Increased Peripheral Blood CD4+ T Cells With Skewing Toward a Treg- and Th2-Dominated Phenotype

  2012cites this paper
• A CD31-derived peptide prevents angiotensin II-induced atherosclerosis progression and aneurysm formation.

  2012cites this paper
• Long term amelioration of established collagen-induced arthritis achieved with short term therapy combining anti-CD3 and anti-TNF treatments

  2012cites this paper
• Impaired Thymic Export and Increased Apoptosis Account for Regulatory T Cell Defects in Patients with Non-ST Segment Elevation Acute Coronary Syndrome*

  2012cites this paper
• Establishment of nasal tolerance to heat shock protein-60 alleviates atherosclerosis by inducing TGF-β-dependent regulatory T cells

  2012cites this paper
• Lymphocyte subset characterization in patients with early clinical presentation of coronary heart disease

  2012cites this paper
• Establishment of nasal tolerance to heat shock protein-60 alleviates atherosclerosis by inducing TGF-β-dependent regulatory T cells

  2012cites this paper
• and therapeutic alternatives for control

  2012cites this paper
• Peptide-Based Vaccination Strategies to Promote Treg-Mediated Atheroprotection

  2012cites this paper
• Alternativas inmunoterapéuticas para el tratamiento de la aterosclerosis

  2012cites this paper
• Regulatory T cells in atherogenesis.

  2012cites this paper
• Procesos moleculares patogénicos de la aterosclerosis y alternativas terapéuticas para su control

  2012cites this paper
• The Role of Immunogenicity in Cardiovascular Disease.

  2011cites this paper
• Implication de l’immunité innée au-delà de la réponse à l’infection — L’athérosclérose: une maladie inflammatoire

  2011cites this paper
• The role of T and B cells in atherosclerosis: potential clinical implications.

  2011cites this paper
• Tissular T(regs): a unique population of adipose-tissue-resident Foxp3+CD4+ T cells that impacts organismal metabolism.

  2011cites this paper
• Amygdalin mediates relieved atherosclerosis in apolipoprotein E deficient mice through the induction of regulatory T cells.

  2011cites this paper
• Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets

  2011cites this paper
• The inflammatory preatherosclerotic remodeling induced by intermittent hypoxia is attenuated by RANTES/CCL5 inhibition.

  2011cites this paper
• Recent Advances on the Role of Cytokines in Atherosclerosis

  2011cites this paper
• Développement d'immunothérapies spécifiques pour le traitement de l'hépatite autoimmune de type 2 chez un modèle murin

  2011cites this paper
• CD3 mAb treatment ameliorated the severity of the cGVHD-induced lupus nephritis in mice by up-regulation of Foxp3+ regulatory T cells in the target tissue: kidney.

  2010cites this paper
• [The role of T-regulatory cells in the pathogenesis of immunological disturbances accompanying obesity and atherosclerosis].

  2010cites this paper
• Circulating CD 4 CD 25 hiCD 127 lo Regulatory T-Cell Levels Do Not Reflect the Extent or Severity of Carotid and Coronary Atherosclerosis

  2010cites this paper
• Immunopathology and Infectious Disease Induction of Active Tolerance and Involvement of CD 1 d-Restricted Natural Killer T Cells in Anti-CD 3 F ( ab ) 2 Treatment-Reversed New-Onset Diabetes in Nonobese Diabetic Mice

  2010cites this paper
• Cellular immune responses to low density lipoprotein in atherosclerosis

  2010cites this paper
• Experimental immunotherapeutic approaches for atherosclerosis.

  2010cites this paper
• Circulating CD4+CD25hiCD127lo Regulatory T-Cell Levels Do Not Reflect the Extent or Severity of Carotid and Coronary Atherosclerosis

  2010cites this paper
• L'athérosclérose: une maladie inflammatoire

  2009cites this paper
• Oral Anti-CD3 Antibody Treatment Induces Regulatory T Cells and Inhibits the Development of Atherosclerosis in Mice

  2009cites this paper
• Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies.

  2009cites this paper
• Cytokine network and T cell immunity in atherosclerosis

  2009cites this paper
• Autoimmune-mediated oxidative stress and endothelial dysfunction: implications of accelerated vascular injury in type I diabetes.

  2009cites this paper
• Regulatory T Cells Modulate Postischemic Neovascularization

  2009cites this paper
• Growth Factors, Cytokines, Cell Cycle Molecules Natural Killer Cells Modulate Overt Autoimmunity to Homeostasis in Nonobese Diabetic Mice after Anti-CD3 F(ab )2 Antibody Treatment through Secreting Transforming Growth Factor-

  2009cites this paper
• Innate and adaptive immunity in atherosclerosis

  2009cites this paper
• The role of adaptive T cell immunity in atherosclerosis Ziad Mallat is a recipient of a Contrat d'Interface from Assistance Publique-Hôpitaux de Paris. Published, JLR Papers in Press, December 2, 2008.

  2009cites this paper
• Cardiovascular consequences of sleep-disordered breathing: contribution of animal models to understanding the human disease.

  2009cites this paper
• THE USE OF REGULATORY T CELLS FOR THE TREATMENT OF ATHEROSCLEROSIS

  2009cites this paper
• Linking diabetes and atherosclerosis

  2009cites this paper
• Upregulation of Angiotensin II Type 2 Receptor (agtr2) Attenuates Atherosclerotic Lesion Formation and Enhances Apoptosis in the LDL Receptor Knockout Mice Fed High Cholesterol Diet

  2009cites this paper
• Vaccination contre l'athérosclérose: lymphocytes T régulateurs et induction de tolérance

  2009cites this paper